For a post-Soliris world, Atlas-backed Q32 Bio outlines $46M next-gen complement play
Long before Alexion kindled a renaissance of complement therapeutics with the introduction of the first anti-C5 antibody, Mike Holers — a longtime professor at the University of Colorado School of Medicine — became fascinated with the host defense system as he completed his rheumatology training. As Soliris begins to fade and follow-on, rivals and even generics catch up to the standard bearer. Holers is debuting a next-generation approach he’s been refining with Atlas Venture over the last two years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.